Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 62 points (0.4%) at 16,880 as of Tuesday, Oct. 28, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,323 issues advancing vs. 662 declining with 163 unchanged.

The Health Care sector currently sits up 0.9% versus the S&P 500, which is up 0.5%. On the negative front, top decliners within the sector include

Aetna

(

AET

), down 3.0%,

Merck

(

MRK

), down 2.7% and

UnitedHealth Group

(

UNH

), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3.

Sanofi

(

SNY

) is one of the companies pushing the Health Care sector lower today. As of noon trading, Sanofi is down $5.11 (-9.7%) to $47.71 on heavy volume. Thus far, 6.0 million shares of Sanofi exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $47.15-$48.60 after having opened the day at $48.22 as compared to the previous trading day's close of $52.82.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Sanofi has a market cap of $142.7 billion and is part of the drugs industry. Shares are up 0.7% year-to-date as of the close of trading on Monday. Currently there are 3 analysts that rate Sanofi a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Sanofi

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, compelling growth in net income, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Sanofi Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading,

GlaxoSmithKline

TheStreet Recommends

(

GSK

) is down $0.38 (-0.8%) to $44.99 on average volume. Thus far, 2.2 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $44.91-$45.21 after having opened the day at $45.19 as compared to the previous trading day's close of $45.37.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $110.0 billion and is part of the drugs industry. Shares are down 14.2% year-to-date as of the close of trading on Monday. Currently there is 1 analyst that rates GlaxoSmithKline a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates

GlaxoSmithKline

as a

buy

. The company's strengths can be seen in multiple areas, such as its notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

GlaxoSmithKline Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading,

Eli Lilly and

(

LLY

) is down $2.15 (-3.2%) to $64.05 on heavy volume. Thus far, 4.3 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 3.9 million shares. The stock has ranged in price between $64.05-$66.10 after having opened the day at $65.99 as compared to the previous trading day's close of $66.20.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $73.8 billion and is part of the drugs industry. Shares are up 29.5% year-to-date as of the close of trading on Monday. Currently there are 6 analysts that rate Eli Lilly and a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Eli Lilly and

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Eli Lilly and Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

null